NZ335312A - Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors to treat humans - Google Patents

Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors to treat humans

Info

Publication number
NZ335312A
NZ335312A NZ335312A NZ33531291A NZ335312A NZ 335312 A NZ335312 A NZ 335312A NZ 335312 A NZ335312 A NZ 335312A NZ 33531291 A NZ33531291 A NZ 33531291A NZ 335312 A NZ335312 A NZ 335312A
Authority
NZ
New Zealand
Prior art keywords
asp
pro
sequence
ala
val
Prior art date
Application number
NZ335312A
Other languages
English (en)
Inventor
Roy A Black
Paul R Sleath
Shirley R Kronheim
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ335312A publication Critical patent/NZ335312A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
NZ335312A 1991-08-30 1991-09-23 Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors to treat humans NZ335312A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75064491A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
NZ335312A true NZ335312A (en) 2005-08-26

Family

ID=25018683

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ335312A NZ335312A (en) 1991-08-30 1991-09-23 Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors to treat humans
NZ248377A NZ248377A (en) 1991-08-30 1991-09-23 Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
NZ239895A NZ239895A (en) 1991-08-30 1991-09-23 Polypeptides with protease activity for interleukin 1beta and their production and use

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ248377A NZ248377A (en) 1991-08-30 1991-09-23 Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
NZ239895A NZ239895A (en) 1991-08-30 1991-09-23 Polypeptides with protease activity for interleukin 1beta and their production and use

Country Status (22)

Country Link
US (2) US5756465A (fr)
EP (2) EP0600880B1 (fr)
JP (3) JP2759895B2 (fr)
KR (1) KR100226296B1 (fr)
AT (1) ATE257517T1 (fr)
AU (1) AU657701B2 (fr)
CA (1) CA2111100C (fr)
DE (1) DE69133354T2 (fr)
DK (1) DK0600880T3 (fr)
ES (1) ES2213138T3 (fr)
FI (1) FI935020A (fr)
HK (1) HK1014013A1 (fr)
HU (1) HU220098B (fr)
IE (1) IE913268A1 (fr)
IL (2) IL99598A (fr)
MX (1) MX9101346A (fr)
MY (1) MY131144A (fr)
NO (1) NO317129B1 (fr)
NZ (3) NZ335312A (fr)
PT (1) PT99118B (fr)
RU (2) RU2206611C2 (fr)
WO (1) WO1993005071A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6995141B1 (en) 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
IL105741A0 (en) * 1992-05-22 1993-09-22 Genta Inc Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
DE69413167T2 (de) * 1993-06-04 1999-05-06 Vertex Pharma Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
EP0711174A4 (fr) * 1993-06-24 1997-11-12 Gen Hospital Corp Genes regulateurs de la mort cellulaire programmee et proteines
US6087160A (en) * 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5955072A (en) * 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
CA2202549C (fr) * 1994-10-14 2003-08-05 Tara Seshadri Animal transgenique comprenant un gene de l'enzyme de conversion d'interleukine-1.beta. a fonction perturbee
CA2215211A1 (fr) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Inhibiteur de la protease de cysteine
US5869315A (en) * 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6416753B1 (en) 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
KR100580333B1 (ko) * 1997-10-10 2006-05-16 시토비아 인크. 디펩티드 고사 억제제 및 그의 용도
WO1999046248A1 (fr) 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated DERIVES DE LA 1,2-DIAZEPANE INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
CA2323439A1 (fr) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptides inhibiteurs de caspase et leur utilisation
PT1064298E (pt) 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
CN1346344A (zh) * 1999-03-16 2002-04-24 西托维亚公司 取代的2－氨基苯甲酰胺天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其应用
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
JP2002541237A (ja) * 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
AU770380B2 (en) * 1999-06-14 2004-02-19 Wisconsin Alumni Research Foundation Oligomers and polymers of cyclic imino carboxylic acids
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2001249619B2 (en) 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
EP1923386A3 (fr) 2000-03-29 2008-05-28 Vertex Pharmceuticals Incorporated Dérivés de carbamates en tant qu'inhibiteurs de caspase et leurs utilisations
WO2001087328A2 (fr) * 2000-05-12 2001-11-22 Immunex Corporation Inhibiteurs d"interleukine 1 dans le traitement de maladies
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
EA006860B1 (ru) * 2002-01-29 2006-04-28 Уайт Композиции и способы модулирования гемиканалов коннексина
US7009053B2 (en) 2002-04-30 2006-03-07 Yungjin Pharmaceuticals Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2004275821A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize N-acyl-L-aspartic acid
CA2566362C (fr) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Traitement de crises epileptiques au moyen d'inhibiteurs ice
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
US7618801B2 (en) * 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease
WO2012061786A1 (fr) 2010-11-05 2012-05-10 Brandeis University Alpha-synucléine clivée ice en tant que marqueur biologique
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2124233B (en) * 1982-07-19 1985-09-18 Nat Res Dev Synthetic peptides and their preparation
US4636492A (en) * 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US5104853A (en) * 1984-12-11 1992-04-14 California Biotechnology Inc. Alveolar surfactant proteins having cys to ser mutations
US4644055A (en) * 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
JPS63145300A (ja) * 1984-12-17 1988-06-17 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− ウイルスにより特定されているプロテア−ゼの特異的阻害剤を製造する方法
US5225354A (en) * 1986-08-22 1993-07-06 Molecular Diagnostics, Inc. Monoclonal antibodies specific for human glycoalbumin
WO1991000912A1 (fr) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production et utilisation d'inhibiteurs de protease hybrides
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5298421A (en) * 1990-04-26 1994-03-29 Calgene, Inc. Plant medium-chain-preferring acyl-ACP thioesterases and related methods
EP0533350B1 (fr) * 1991-08-16 1999-05-26 Merck & Co. Inc. ADN codant l'enzyme de conversion du précurseur de l'interleukine 1B
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok

Also Published As

Publication number Publication date
WO1993005071A1 (fr) 1993-03-18
US6136787A (en) 2000-10-24
IL99598A0 (en) 1992-08-18
EP0600880A4 (fr) 1994-12-21
CA2111100C (fr) 2004-11-02
IL99598A (en) 2005-06-19
HUT66057A (en) 1994-09-28
KR100226296B1 (ko) 1999-10-15
HU9303244D0 (en) 1994-03-28
JP2001192397A (ja) 2001-07-17
RU94028712A (ru) 1997-03-10
ES2213138T3 (es) 2004-08-16
HU220098B (hu) 2001-10-28
EP1378573A1 (fr) 2004-01-07
IL166791A0 (en) 2006-01-15
ATE257517T1 (de) 2004-01-15
RU2002128757A (ru) 2004-07-27
PT99118A (pt) 1993-02-26
AU657701B2 (en) 1995-03-23
NO934335D0 (no) 1993-11-30
EP0600880A1 (fr) 1994-06-15
JPH1028588A (ja) 1998-02-03
FI935020A (fi) 1993-12-03
NO934335L (no) 1993-11-30
CA2111100A1 (fr) 1993-03-18
DE69133354D1 (de) 2004-02-12
HK1014013A1 (en) 1999-09-17
AU8537391A (en) 1993-04-05
FI935020A0 (fi) 1993-11-12
EP0600880B1 (fr) 2004-01-07
RU2206611C2 (ru) 2003-06-20
JP3445572B2 (ja) 2003-09-08
DE69133354T2 (de) 2004-11-11
NZ248377A (en) 2000-01-28
US5756465A (en) 1998-05-26
DK0600880T3 (da) 2004-04-13
NO317129B1 (no) 2004-08-23
NZ239895A (en) 1996-01-26
IE913268A1 (en) 1993-03-10
JPH08505280A (ja) 1996-06-11
PT99118B (pt) 1999-02-26
MX9101346A (es) 1993-02-01
JP2759895B2 (ja) 1998-05-28
MY131144A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
EP0600880B1 (fr) Interleukine 1-beta protease et inhibiteurs d'interleukine 1-beta protease
US5416013A (en) Interleukin 1β protease and interleukin 1β protease inhibitors
WO1991015577A1 (fr) INTERLEUKIN 1'beta' PROTEASE
US6599873B1 (en) Interleukin-1 inhibitors, compositions, and methods of treatment
US6080398A (en) Truncated gro and KC chemokines having enhanced bioactivity
US6025467A (en) Parathyroid hormone derivatives and their use
JPH03163099A (ja) 腫瘍壊死因子（ｔｎｆ）インヒビターおよびその製造方法
IE842398L (en) Growth hormone release factor analogs
BG60256B2 (bg) Рекомбинантен метод за получаване на лимфотоксин
DK172763B1 (da) Isoleret interleukin-1 (IL-1) inhibitor eller forstadiepolypeptid dertil, isoleret DNA-molekyle, som koder derfor, vektor o
WO1993024634A1 (fr) Dipeptidyle peptidase-i, son clonage et agents therapeutiques contenant des inhibiteurs de cette substance
CA2139127A1 (fr) Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation
NO893452L (no) Rekombinant naturlig dreper-celleaktivator.
US20060188474A1 (en) Interleukin 1beta protease and interleukin 1beta protease inhibitors
JPH09157294A (ja) 副甲状腺ホルモン誘導体
ES2295370T3 (es) Nueva aminopeptidasa derivada de bacillus licheniformis, gen que codifica la aminopeptidasa, vector de expresion que contiene el gen, transformante y metodo para su preparacion.
AU690264B2 (en) Superactive GRF analogs
AU633831C (en) Interleukin-1 inhibitors
JPH05239093A (ja) Ｇｍ−コロニー刺激因子阻害オリゴペプチド
CA2098777A1 (fr) Production de cathepsine humaine et son utilisation
HU211309A9 (hu) Új polipeptid és előállítása

Legal Events

Date Code Title Description
AVOD Application void
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
EXPY Patent expired
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127